GlassScriptPhysician profile
Chandni Duphare
NPI 1922568583
$924.43
in general payments reported to CMS, 2019-2025
8 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
See the full distribution for Uveitis and Ocular Inflammatory Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.99 · 2021: $75.71 · 2022: $146 · 2023: $469 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.88 | 2022-2025 | Xen Glaucoma Treatment System, Ozurdex |
| Alimera Sciences, INC. | $140.98 | 2023 | Iluvien |
| Alcon Vision LLC | $106.16 | 2021-2025 | Tryptyr, Clareon |
| Allergan, INC. | $99.99 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $25.34 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.99 | 2021 | |
| Omeros Corporation | $18.74 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandni Duphare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.